Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04685811 · ClinicalTrials.gov registry record · Phase 1
Evaluation of PSMA Antagonist Produced by Two Different Methods
A Phase 1 study of Metastatic Prostate Adenocarcinoma, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04685811 is a Phase 1 study of Metastatic Prostate Adenocarcinoma that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 16 participants, below the 125-participant average among 18 other Metastatic Prostate Adenocarcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04685811, a Phase 1 study of Metastatic Prostate Adenocarcinoma, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers. The goal of the study is to evaluate repeatability and equivalence across the different 68Ga-PSMA production methods. This research study is being conducted to assess whether the PET/CT imaging results, as generated from the two different 68Ga production methods, are equivalent.
Conditions Studied
Interventions
- DRUG 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04685811
The ClinicalTrials.gov registry entry for NCT04685811 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 18 other Metastatic Prostate Adenocarcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron is the first listed.
NCT04685811 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04685811 about?
NCT04685811 is a clinical study titled "Evaluation of PSMA Antagonist Produced by Two Different Methods". Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers. The goal of the study is to evaluate repeatability and equivalence across the different 68Ga-PSMA production methods. This research stud...
What is the current status of trial NCT04685811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-12-09. Estimated completion is 2021-06-30.
What conditions does trial NCT04685811 study?
This clinical trial studies the following conditions: Metastatic Prostate Adenocarcinoma.
What interventions are being tested in trial NCT04685811?
The interventions under investigation include: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron (DRUG).
Who is sponsoring clinical trial NCT04685811?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04685811 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 1
-
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
ACTIVE NOT RECRUITING · Phase 1
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.